Adiponectin: An indicator for metabolic syndrome

Somaye Yosaee, Mahmoud Khodadost, Alireza Esteghamati, John R. Speakman, Kurosh Djafarian, Vida Bitarafan, Farzad Shidfar (Corresponding Author)

Research output: Contribution to journalArticle

Abstract

Background: Metabolic syndrome (MetS), a cluster of cardiometabolic risk factors, consider as a manifestation of obesity. However, a proportion of obese patients do not develop MetS. The aim of our study was to determine whether concentration of plasma adiponectin and leptin differ between metabolic unhealthy obese (MUO) patients and comparable age-and sex-matched control groups. Methods: In this case-control study, we assigned 51 obese patients with MetS (MUO) in cases group and 102 metabolic healthy obese (MHO) and normal weight metabolic healthy subjects matched for age and gender to cases in control groups. The study was conducted between December 2014 and February 2016 in the Endocrinology Research Center of Tehran University of Medical Sciences, Tehran, Iran. We measured serum adiponectin, leptin, their ratio, and body composition in all subjects. Results: No significant differences were observed between MHO and MUO in term of total fat mass and trunk fat (P>0.05). Compared to MHO and normal weight metabolic healthy subjects, MUO subjects had lower levels of plasma adiponectin (P<0.001) and lower plasma adiponectin to leptin ratio (P<0.001) and a higher level of plasma leptin (P<0.002). A Receiver Operator Characteristic curve was used to identify the ability of adiponectin and leptin level to predict the MetS. The area under the Receiver Operator Characteristic curve was 0.66 (P<0.01), 0.73 (P<0.001) and 0.75 (P<0.001) for leptin, adiponectin, and adiponectin/leptin ratio levels respectively. Conclusion: Our study introduced adiponectin and leptin as indicator of MetS and obesity respectively.

Original languageEnglish
Pages (from-to)1106-1115
Number of pages10
JournalIranian Journal of Public Health
Volume48
Issue number6
Publication statusPublished - 2 Jun 2019

Fingerprint

Adiponectin
Leptin
Healthy Volunteers
Obesity
Fats
Weights and Measures
Control Groups
Endocrinology
Iran
Body Composition
Case-Control Studies
Research Design
Serum
Research

Keywords

  • Adiponectin
  • Fat mass
  • Leptin
  • Metabolic syndrome

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Yosaee, S., Khodadost, M., Esteghamati, A., Speakman, J. R., Djafarian, K., Bitarafan, V., & Shidfar, F. (2019). Adiponectin: An indicator for metabolic syndrome. Iranian Journal of Public Health, 48(6), 1106-1115.

Adiponectin : An indicator for metabolic syndrome. / Yosaee, Somaye; Khodadost, Mahmoud; Esteghamati, Alireza; Speakman, John R.; Djafarian, Kurosh; Bitarafan, Vida; Shidfar, Farzad (Corresponding Author).

In: Iranian Journal of Public Health, Vol. 48, No. 6, 02.06.2019, p. 1106-1115.

Research output: Contribution to journalArticle

Yosaee, S, Khodadost, M, Esteghamati, A, Speakman, JR, Djafarian, K, Bitarafan, V & Shidfar, F 2019, 'Adiponectin: An indicator for metabolic syndrome' Iranian Journal of Public Health, vol. 48, no. 6, pp. 1106-1115.
Yosaee S, Khodadost M, Esteghamati A, Speakman JR, Djafarian K, Bitarafan V et al. Adiponectin: An indicator for metabolic syndrome. Iranian Journal of Public Health. 2019 Jun 2;48(6):1106-1115.
Yosaee, Somaye ; Khodadost, Mahmoud ; Esteghamati, Alireza ; Speakman, John R. ; Djafarian, Kurosh ; Bitarafan, Vida ; Shidfar, Farzad. / Adiponectin : An indicator for metabolic syndrome. In: Iranian Journal of Public Health. 2019 ; Vol. 48, No. 6. pp. 1106-1115.
@article{720e4ace46344b6e8f3ac5eb95e02857,
title = "Adiponectin: An indicator for metabolic syndrome",
abstract = "Background: Metabolic syndrome (MetS), a cluster of cardiometabolic risk factors, consider as a manifestation of obesity. However, a proportion of obese patients do not develop MetS. The aim of our study was to determine whether concentration of plasma adiponectin and leptin differ between metabolic unhealthy obese (MUO) patients and comparable age-and sex-matched control groups. Methods: In this case-control study, we assigned 51 obese patients with MetS (MUO) in cases group and 102 metabolic healthy obese (MHO) and normal weight metabolic healthy subjects matched for age and gender to cases in control groups. The study was conducted between December 2014 and February 2016 in the Endocrinology Research Center of Tehran University of Medical Sciences, Tehran, Iran. We measured serum adiponectin, leptin, their ratio, and body composition in all subjects. Results: No significant differences were observed between MHO and MUO in term of total fat mass and trunk fat (P>0.05). Compared to MHO and normal weight metabolic healthy subjects, MUO subjects had lower levels of plasma adiponectin (P<0.001) and lower plasma adiponectin to leptin ratio (P<0.001) and a higher level of plasma leptin (P<0.002). A Receiver Operator Characteristic curve was used to identify the ability of adiponectin and leptin level to predict the MetS. The area under the Receiver Operator Characteristic curve was 0.66 (P<0.01), 0.73 (P<0.001) and 0.75 (P<0.001) for leptin, adiponectin, and adiponectin/leptin ratio levels respectively. Conclusion: Our study introduced adiponectin and leptin as indicator of MetS and obesity respectively.",
keywords = "Adiponectin, Fat mass, Leptin, Metabolic syndrome",
author = "Somaye Yosaee and Mahmoud Khodadost and Alireza Esteghamati and Speakman, {John R.} and Kurosh Djafarian and Vida Bitarafan and Farzad Shidfar",
note = "Our research group would like to thank all subjects who took part in current study. The project was financially supported by the Iran University of Medical Sciences. (93-02-27-24976)",
year = "2019",
month = "6",
day = "2",
language = "English",
volume = "48",
pages = "1106--1115",
journal = "Iranian Journal of Public Health",
issn = "2251-6085",
number = "6",

}

TY - JOUR

T1 - Adiponectin

T2 - An indicator for metabolic syndrome

AU - Yosaee, Somaye

AU - Khodadost, Mahmoud

AU - Esteghamati, Alireza

AU - Speakman, John R.

AU - Djafarian, Kurosh

AU - Bitarafan, Vida

AU - Shidfar, Farzad

N1 - Our research group would like to thank all subjects who took part in current study. The project was financially supported by the Iran University of Medical Sciences. (93-02-27-24976)

PY - 2019/6/2

Y1 - 2019/6/2

N2 - Background: Metabolic syndrome (MetS), a cluster of cardiometabolic risk factors, consider as a manifestation of obesity. However, a proportion of obese patients do not develop MetS. The aim of our study was to determine whether concentration of plasma adiponectin and leptin differ between metabolic unhealthy obese (MUO) patients and comparable age-and sex-matched control groups. Methods: In this case-control study, we assigned 51 obese patients with MetS (MUO) in cases group and 102 metabolic healthy obese (MHO) and normal weight metabolic healthy subjects matched for age and gender to cases in control groups. The study was conducted between December 2014 and February 2016 in the Endocrinology Research Center of Tehran University of Medical Sciences, Tehran, Iran. We measured serum adiponectin, leptin, their ratio, and body composition in all subjects. Results: No significant differences were observed between MHO and MUO in term of total fat mass and trunk fat (P>0.05). Compared to MHO and normal weight metabolic healthy subjects, MUO subjects had lower levels of plasma adiponectin (P<0.001) and lower plasma adiponectin to leptin ratio (P<0.001) and a higher level of plasma leptin (P<0.002). A Receiver Operator Characteristic curve was used to identify the ability of adiponectin and leptin level to predict the MetS. The area under the Receiver Operator Characteristic curve was 0.66 (P<0.01), 0.73 (P<0.001) and 0.75 (P<0.001) for leptin, adiponectin, and adiponectin/leptin ratio levels respectively. Conclusion: Our study introduced adiponectin and leptin as indicator of MetS and obesity respectively.

AB - Background: Metabolic syndrome (MetS), a cluster of cardiometabolic risk factors, consider as a manifestation of obesity. However, a proportion of obese patients do not develop MetS. The aim of our study was to determine whether concentration of plasma adiponectin and leptin differ between metabolic unhealthy obese (MUO) patients and comparable age-and sex-matched control groups. Methods: In this case-control study, we assigned 51 obese patients with MetS (MUO) in cases group and 102 metabolic healthy obese (MHO) and normal weight metabolic healthy subjects matched for age and gender to cases in control groups. The study was conducted between December 2014 and February 2016 in the Endocrinology Research Center of Tehran University of Medical Sciences, Tehran, Iran. We measured serum adiponectin, leptin, their ratio, and body composition in all subjects. Results: No significant differences were observed between MHO and MUO in term of total fat mass and trunk fat (P>0.05). Compared to MHO and normal weight metabolic healthy subjects, MUO subjects had lower levels of plasma adiponectin (P<0.001) and lower plasma adiponectin to leptin ratio (P<0.001) and a higher level of plasma leptin (P<0.002). A Receiver Operator Characteristic curve was used to identify the ability of adiponectin and leptin level to predict the MetS. The area under the Receiver Operator Characteristic curve was 0.66 (P<0.01), 0.73 (P<0.001) and 0.75 (P<0.001) for leptin, adiponectin, and adiponectin/leptin ratio levels respectively. Conclusion: Our study introduced adiponectin and leptin as indicator of MetS and obesity respectively.

KW - Adiponectin

KW - Fat mass

KW - Leptin

KW - Metabolic syndrome

UR - http://www.scopus.com/inward/record.url?scp=85067274310&partnerID=8YFLogxK

M3 - Article

VL - 48

SP - 1106

EP - 1115

JO - Iranian Journal of Public Health

JF - Iranian Journal of Public Health

SN - 2251-6085

IS - 6

ER -